{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:05:57Z","timestamp":1760123157529,"version":"build-2065373602"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.lpm.2022.104125","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T11:44:43Z","timestamp":1652183083000},"page":"104125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["New developments in skin-directed treatments of cutaneous T-cell lymphoma"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4545-7472","authenticated-orcid":false,"given":"Iris","family":"Amitay-Laish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2022.104125_bib0001","unstructured":"National Comprehensive Cancer network clinical Practice Guidelines in Oncology. Primary Cutaneous Lymphomas. Version 2.2021"},{"key":"10.1016\/j.lpm.2022.104125_bib0002","doi-asserted-by":"crossref","first-page":"Iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2022.104125_bib0003","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/sezary syndrome - update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lpm.2022.104125_bib0004","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.19252","article-title":"Treatment of early-stage mycosis fungoides: results from the PROspective cutaneous lymphoma international prognostic index (PROCLIPI) study","volume":"184","author":"Quaglino","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0005","first-page":"220","article-title":"Review of the treatment of mycosis fungoides and sezary syndrome: a stage-based approach","volume":"7","author":"Al Hothali","year":"2013","journal-title":"Int J Health Sci (Qassim)"},{"key":"10.1016\/j.lpm.2022.104125_bib0006","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.lpm.2022.104125_bib0008","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/1097-0142(196602)19:2<237::AID-CNCR2820190216>3.0.CO;2-P","article-title":"Therapy of mycosis fungoides with topically applied fluocinolone acetonide under occlusive dressing","volume":"19","author":"Farber","year":"1966","journal-title":"Cancer"},{"key":"10.1016\/j.lpm.2022.104125_bib0009","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaad.2020.05.043","article-title":"Response to topical corticosteroid monotherapy in mycosis fungoides","volume":"84","author":"Kartan","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0010","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-021-00539-3","article-title":"Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience","author":"Geskin","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.lpm.2022.104125_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0012","first-page":"1","article-title":"Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine\/mechlorethamine gel in patients with stage IA-IIA mycosis fungoides","volume":"4","author":"Querfeld","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.lpm.2022.104125_bib0013","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jid.2020.12.009","article-title":"Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"141","author":"Querfeld","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","article-title":"The PROVe study: US real-world experience with chlormethine\/echlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jaad.2019.12.070","article-title":"Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma. Preliminary findings from a prospective observational study","volume":"83","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/ddg.14462","article-title":"Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers","author":"Wehkamp","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.lpm.2022.104125_bib0017","first-page":"878","article-title":"Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis","volume":"6","author":"Gilmore","year":"2020","journal-title":"JADD Case Rep"},{"key":"10.1016\/j.lpm.2022.104125_bib0018","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0190-9622(90)70112-U","article-title":"Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients","volume":"22","author":"Zackheim","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0019","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1396-0296.2003.01641.x","article-title":"Topical carmustine (BCNU) in the treatment of mycosis fungoides","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.lpm.2022.104125_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2340\/00015555-2551","article-title":"Topical carmustine as monotherapy or as multimodality therapy for folliculotropic mycosis fungoides","volume":"97","author":"MacArthur","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.lpm.2022.104125_bib0021","doi-asserted-by":"crossref","first-page":"adv00187","DOI":"10.2340\/00015555-3443","article-title":"Pilot study of a novel therapeutic approach for refractory advanced stage folliculotropic mycosis fungoides","volume":"100","author":"Del Guzzo","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.lpm.2022.104125_bib0022","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1001\/jama.1984.03340410063036","article-title":"Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"251","author":"Goodman","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2022.104125_bib0023","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2133.1977.tb15429.x","article-title":"Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides","volume":"97","author":"Zackheim","year":"1977","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0024","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0025","first-page":"169","article-title":"Folliculotropic mycosis fungoides responding to bexarotene gel","volume":"7","author":"Walling","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0026","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1468-3083.2011.04383.x","article-title":"Childhood mycosis fungoides: a report of 20 cases from Turkey","volume":"27","author":"Yazganoglu","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.lpm.2022.104125_bib0027","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1111\/ijd.14555","article-title":"Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later","volume":"58","author":"Ramachandran","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0028","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dth.12281","article-title":"Woringer\u2013Kolopp (Pagetoid Reticulosis) disease successful response to bexarotene gel","volume":"29","author":"Ledet","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.lpm.2022.104125_bib0029","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2003.09.005","article-title":"Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study","volume":"50","author":"Apisarnthanarax","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1389557516666151217122758","article-title":"Imidazoquinolines: recent developments in anticancer activity","volume":"16","author":"Patil","year":"2016","journal-title":"Mini Rev Med"},{"key":"10.1016\/j.lpm.2022.104125_bib0031","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/CCO.0000000000000048","article-title":"Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma","volume":"26","author":"Huen","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.lpm.2022.104125_bib0032","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13555-019-00317-2","article-title":"Revisiting imiquimod for treatment of folliculotropic mycosis fungoides: a case report and review of the literature","volume":"9","author":"Shalabi","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.lpm.2022.104125_bib0033","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","article-title":"Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0034","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000070962","article-title":"Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides","volume":"207","author":"Dummer","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.lpm.2022.104125_bib0037","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/09546630310019373","article-title":"Imiquimod 5% cream in the treatment of mycosis fungoides\u2014A pilot study","volume":"15","author":"Chong","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.lpm.2022.104125_bib0036","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2004.04.049","article-title":"Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream","volume":"52","author":"Deeths","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0035","first-page":"391","article-title":"Topical imiquimod as treatment for different kinds of cutaneous lymphoma","volume":"16","author":"Coors","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0038","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2133.2006.07599.x","article-title":"Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy","volume":"156","author":"Chiam","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0039","first-page":"148","article-title":"Imiquimod in mycosis fungoides","volume":"18","author":"Martinez-Gonzalez","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0040","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jdcr.2015.08.007","article-title":"Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod","volume":"1","author":"Gordon","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.lpm.2022.104125_bib0041","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/09546634.2017.1294728","article-title":"Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series","volume":"28","author":"Lewis","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.lpm.2022.104125_bib0042","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jdv.12718","article-title":"Treatment of localized pagetoid reticulosis with imiquimod: a case report and literature review","volume":"30","author":"Su","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.lpm.2022.104125_bib0043","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2022.104125_bib0044","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","article-title":"Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8","volume":"174","author":"Gorden","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2022.104125_bib0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.det.2015.05.005","article-title":"Phototherapy of mycosis fungoides","volume":"33","author":"Hodak","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.lpm.2022.104125_bib0046","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and sezary syndrome: a consensus statement of the United States cutaneous lymphoma consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0047","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2340\/00015555-3013","article-title":"Treatment of early folliculotropic mycosis fungoides with special focus on psoralen plus ultraviolet A","volume":"98","author":"Amitay-Laish","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.lpm.2022.104125_bib0048","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamadermatol.2018.5204","article-title":"Comparison of narrowband UV-B with psoralen-UV-a phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis","volume":"155","author":"Phan","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0049","doi-asserted-by":"crossref","first-page":"306","DOI":"10.23736\/S0392-0488.18.05867-4","article-title":"Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1","volume":"155","author":"Trovato","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.lpm.2022.104125_bib0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.det.2004.11.001","article-title":"Using light in dermatology: an update on lasers, ultraviolet phototherapy, and photodynamic therapy","volume":"23","author":"Hamzavi","year":"2005","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.lpm.2022.104125_bib0051","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jaad.2014.01.915","article-title":"Excimer laser in the treatment of mycosis fungoides","volume":"70","author":"Deaver","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0052","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2133.2010.09793.x","article-title":"Excimer laser therapy (308\u00a0nm) for mycosis fungoides palmaris et plantaris: a skin-directed and anatomically feasible treatment","volume":"163","author":"Jin","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0053","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/pho.2008.2317","article-title":"Different applications of monochromatic excimer light in skin diseases","volume":"27","author":"Nistico","year":"2009","journal-title":"Photomed Laser Surg"},{"key":"10.1016\/j.lpm.2022.104125_bib0054","doi-asserted-by":"crossref","first-page":"251","DOI":"10.15171\/jlms.2019.40","article-title":"Successful use of the 308-nm excimer laser in early patch stage mycosis fungoides","volume":"10","author":"Armenta","year":"2019","journal-title":"J Lasers Med Sci"},{"key":"10.1016\/j.lpm.2022.104125_bib0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5021\/ad.2018.30.1.93","article-title":"Hypopigmented mycosis fungoides treated with 308\u00a0nm excimer laser","volume":"30","author":"Yang","year":"2018","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0056","doi-asserted-by":"crossref","DOI":"10.1111\/phpp.12698","article-title":"Photodynamic therapy of mycosis fungoides: a systematic review of case studies","author":"Hooper","year":"2021","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.lpm.2022.104125_bib0057","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0190-9622(03)00868-5","article-title":"Topical photodynamic therapy for patients with therapy resistant lesions of cutaneous T-cell lymphoma","volume":"50","author":"Coors","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.lpm.2022.104125_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.01.053","article-title":"Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: a prospective, open-label study","author":"Severson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0059","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/jdv.14160","article-title":"Unilesional plantar mycosis fungoides treated with topical photodynamic therapy - case report and review of the literature","volume":"31","author":"Kaufmann","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.lpm.2022.104125_bib0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5021\/ad.2018.30.2.192","article-title":"Folliculotropic mycosis fungoides in 20 Korean cases: clinical and histopathologic features and response to ultraviolet A-1 and\/or photodynamic therapy","volume":"30","author":"Jang","year":"2018","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0061","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/ced.13936","article-title":"Localized mycosis fungoides treated with laser-assisted photodynamic therapy: a case series","volume":"44","author":"Dairi","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0062","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International lymphoma radiation oncology group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lpm.2022.104125_bib0063","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lpm.2022.104125_bib0064","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-18-4147","article-title":"Radiotherapy eradicates malignant T cells and is associated with improved survival in early-stage mycosis fungoides","volume":"26","author":"O'Malley","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2022.104125_bib0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the European organization for research and treatment of cancer (EORTC) cutaneous lymphoma project group","volume":"47","author":"Jones","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0066","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.ijrobp.2011.01.023","article-title":"Revisiting low dose total skin electron beam therapy in mycosis fungoides","volume":"81","author":"Harrison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lpm.2022.104125_bib0067","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.lpm.2022.104125_bib0068","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ijrobp.2017.05.052","article-title":"The results of low-dose total skin electron beam radiation therapy (TSEB) in patients with mycosis fungoides from the UK cutaneous lymphoma group","volume":"99","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lpm.2022.104125_bib0069","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2018.12.003","article-title":"Multi-institutional investigation: circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides","volume":"131","author":"An","year":"2019","journal-title":"Radiother Oncol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:56Z","timestamp":1760105276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498222000185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0755498222000185"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104125","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New developments in skin-directed treatments of cutaneous T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"104125"}}